|
|
Blood, 15 October 2007, Vol. 110, No. 8, pp. 2899-2906.
Prepublished online as a Blood First Edition Paper on July 5, 2007; DOI 10.1182/blood-2007-01-064428.
Previous Article | Table of Contents | Next Article 
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Nucleolin is a receptor that mediates antiangiogenic and antitumor activity of endostatin
Hubing Shi1,
Yujie Huang1,
Hao Zhou1,
Xiaomin Song1,
Shaopeng Yuan1,
Yan Fu1, and
Yongzhang Luo1
1 Laboratory of Protein Chemistry, the Protein Science Laboratory of the Ministry of Education, Department of Biological Sciences and Biotechnology, Tsinghua University, Beijing, People's Republic of China
The exact molecular mechanism of how endostatin inhibits angiogenesis and tumor growth remains uncharacterized. Here, we report that endostatin specifically binds to the cell surface nucleolin with high affinity. Blockage of nucleolin by a neutralizing antibody or knockdown of nucleolin by the RNA interference results in loss of antiendothelial activities of endostatin. Importantly, a neutralizing antinucleolin antibody abrogates the antiangiogenic and antitumor activities of endostatin in vivo. Nucleolin and endostatin are colocalized on the cell surface of endothelial cells of angiogenic blood vessels in the tumor environment. Finally, we found that endostatin is internalized and transported into cell nuclei of endothelial cell via nucleolin. In the nucleus, the phosphorylation of nucleolin, which is critical for cell proliferation, can be inhibited by endostatin. Our studies demonstrate that nucleolin is a novel functional receptor for endostatin, and mediates the antiangiogenic and antitumor activities of endostatin. These findings also provide mechanistic insights of how endostatin specifically inhibits proliferating endothelial cell growth and angiogenesis.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Article in Blood Online:
-
Endostatin finds a new partner: nucleolin
- Judah Folkman
Blood 2007 110: 2786-2787.
[Full Text]
[PDF]
This article has been cited by other articles:

|
 |

|
 |
 
Y. Huang, N. Song, Y. Ding, S. Yuan, X. Li, H. Cai, H. Shi, and Y. Luo
Pulmonary Vascular Destabilization in the Premetastatic Phase Facilitates Lung Metastasis
Cancer Res.,
October 1, 2009;
69(19):
7529 - 7537.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Song, Y. Huang, H. Shi, S. Yuan, Y. Ding, X. Song, Y. Fu, and Y. Luo
Overexpression of Platelet-Derived Growth Factor-BB Increases Tumor Pericyte Content via Stromal-Derived Factor-1{alpha}/CXCR4 Axis
Cancer Res.,
August 1, 2009;
69(15):
6057 - 6064.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Yuan, Y. Fu, X. Wang, H. Shi, Y. Huang, X. Song, L. Li, N. Song, and Y. Luo
Voltage-dependent anion channel 1 is involved in endostatin-induced endothelial cell apoptosis
FASEB J,
August 1, 2008;
22(8):
2809 - 2820.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Stepanova, T. Lebedeva, A. Kuo, S. Yarovoi, S. Tkachuk, S. Zaitsev, K. Bdeir, I. Dumler, M. S. Marks, Y. Parfyonova, et al.
Nuclear translocation of urokinase-type plasminogen activator
Blood,
July 1, 2008;
112(1):
100 - 110.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. N. Re and J. L. Cook
The Basis of an Intracrine Pharmacology
J. Clin. Pharmacol.,
March 1, 2008;
48(3):
344 - 350.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|